Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 2

Status

Completed 4Unknown 3Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

toripalimab 1spartalizumab 1Injections 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Advanced Malignant Tumors × Clear all
NCT05779163 2026-05-14

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
26 enrolled

Advanced Malignant Tumors

NCT05214482 2026-03-03

A Study of AK112 in Advanced Malignant Tumors

Akeso

Phase 1/2 Completed
154 enrolled

Advanced Malignant Tumors

NCT05223231 2026-02-02

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
26 enrolled

Advanced Malignant Tumors

NCT05102006 2025-06-03

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
80 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡